Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5528095 | 0.86 | CASP1 (0.44) | CYP3A4ALOX15CHRM1MAOATBXA2R | |
| SCHEMBL24622828 | 0.86 | CYP3A4 (0.52) | CYP3A4ALOX15CHRM1MAOATBXA2R | |
| SCHEMBL26694609 | 0.82 | GAA (0.46) | CYP3A4ALOX15CHRM1MAOATBXA2R | |
| SCHEMBL23205851 | 0.82 | CYP3A4 (0.38) | CYP3A4ALOX15CHRM1MAOATBXA2R | |
| SCHEMBL27653140 | 0.82 | ALDH1A1 (0.52) | CYP3A4ALOX15CHRM1MAOATBXA2R | |
| SCHEMBL525487 | 0.78 | GAA (0.42) | CYP3A4ALDH1A1TSHRMAPTGAA | |
| SCHEMBL26885126 | 0.78 | NOS3 (0.39) | CYP3A4ALOX15CHRM1MAOATBXA2R | |
| SCHEMBL26890853 | 0.78 | LMNA (0.39) | CYP3A4ALOX15CHRM1MAOATBXA2R | |
| SCHEMBL28860176 | 0.77 | ALDH1A1 (0.40) | CYP3A4ALOX15CHRM1MAOATBXA2R | |
| SCHEMBL25077717 | 0.77 | GAA (0.42) | CYP3A4ALOX15CHRM1MAOATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-16 | — | — | US | disclosed |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-02-26 | — | — | US | disclosed |
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12331049-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-12331050-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-RE50455-E1 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-10 | — | — | US | disclosed |
| US-20250092041-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12187724-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20250002494-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-01-02 | — | — | US | disclosed |
| US-20240262824-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-08-08 | — | — | US | disclosed |
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| US-4101575-A | FUNGICIDES, BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-18 | — | — | US | disclosed |
| US-4036850-A | FUNGICIDES, HERBICIDES, BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | CYP3A4 2881/4885ALOX15 3410/4885CHRM1 1376/4885 |
| US-12331049-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | CYP3A4 2881/4885ALOX15 3410/4885CHRM1 1376/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | CYP3A4 4198/4885ALOX15 2913/4885CHRM1 828/4885 |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | CYP3A4 1988/4885ALOX15 2937/4885CHRM1 58/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | CYP3A4 4807/4885ALOX15 4133/4885CHRM1 2058/4885 |
| US-12187724-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | CYP3A4 2881/4885ALOX15 3410/4885CHRM1 1376/4885 |
| US-20250002494-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | CYP3A4 2881/4885ALOX15 3410/4885CHRM1 1376/4885 |
| US-20240262824-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | CYP3A4 2881/4885ALOX15 3410/4885CHRM1 1376/4885 |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GIPR, GPR119 | CYP3A4 2193/4885ALOX15 1683/4885CHRM1 1024/4885 |
| US-12331050-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | CYP3A4 2881/4885ALOX15 3410/4885CHRM1 1376/4885 |
| US-20250092041-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | CYP3A4 2648/4885ALOX15 3669/4885CHRM1 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.